H.R. 8370: Dietary Supplement Listing Act of 2026

The Dietary Supplement Listing Act of 2026 aims to increase transparency and ensure better access to information regarding dietary supplements in the United States by requiring manufacturers to list these products with the Food and Drug Administration (FDA). Here are the key aspects of the bill:

Listing Requirements

Starting from a date specified in the bill, all dietary supplements sold in the U.S. must be officially listed with the Secretary of Health and Human Services. This listing must include:

• The name and identity statement of the supplement, including brand and flavors.
• The responsible person’s name and address, along with the contact information for the agent in charge.
• An electronic copy of the product label.
• A complete list of ingredients, including amounts per serving and allergen information.
• Directions for use and any applicable warnings.
• The form of the supplement (e.g., tablet, capsule, powder).
• The dietary supplement product listing number provided by the Secretary.

Submission Process

The responsible party for the supplement (manufacturer, packer, or distributor) must submit the required information electronically. Upon filing, the Secretary must notify the responsible person whether the submission is complete or if additional information is needed.

Timeline for Compliance

For dietary supplements currently on the market, manufacturers must submit their listings within 18 months after the bill becomes law. New dietary supplements must be listed at the time they are introduced to the market. If a supplement is discontinued, manufacturers must notify the FDA within one year of cessation.

Database Creation

Within two years after the enactment, the Secretary will create a publicly accessible electronic database that includes all listed dietary supplements. It will allow users to search for supplement information easily. Certain sensitive information related to business can be withheld to protect proprietary details.

Funding

The bill authorizes specific funding amounts for implementation, with an allocation of approximately $7.87 million for fiscal year 2026 and about $6.61 million for subsequent years until 2030 to effectively carry out these regulatory activities.

Consequences of Non-Compliance

If a responsible person fails to comply with the listing requirements, the supplement may be classified as misbranded under existing regulations, potentially leading to legal repercussions or enforcement actions.

Relevant Companies

• GSN - General Nutrition Centers, a major dietary supplement retailer, may need to adjust labeling and product listings to comply with new regulations.
• NVDA - Companies related to supplement manufacturing that may need to adapt their operations and compliance mechanisms to adhere to the new FDA requirements.
• AMGN - Amgen, which produces dietary supplements, could see impacts on their market practices and compliance costs.